Updates in the Management of HIV During Pregnancy
- PMID: 38946602
- DOI: 10.1097/GRF.0000000000000887
Updates in the Management of HIV During Pregnancy
Abstract
Human immunodeficiency virus in pregnant people remains a significant public health issue worldwide. The rate of perinatal transmission is 15% to 40% but can be decreased to less than 1% with appropriate antenatal management. Previous recommendations included a protease inhibitor-based antiretroviral therapy, infant prophylaxis, performance of cesarean section for uncontrolled viremia, and the use of formula for infant feeding. However, recent updates include first line of integrase inhibitor-based regimens and supporting parental choices for safe lactation. In this review, we summarize and provide updated recommendations for the care of people living with human immunodeficiency virus during pregnancy.
Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.
References
-
- United Nations Women. Facts and figures: HIV and AIDS. Accessed April 14, 2023. https://www.unwomen.org/en/what-we-do/hiv-and-aids/facts-and-figures
-
- Centers for Disease Control and Prevention HIV surveillance report. 2021;2023:34. Accessed November 13. https://www.hiv.gov/blog/cdc-publishes-new-hiv-surveillance-reports
-
- Lampe MA, Nesheim SR, Oladapo KL, et al. Achieving elimination of perinatal HIV in the United States. Pediatrics. 2023;151:e2022059604.
-
- Kourtis AP, Read JS, Jamieson DJ. Pregnancy and infection. N Engl J Med. 2014;370:2211–2218.
-
- Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med. 1994;331:1173–1180.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical